(ARVN) Arvinas, Inc. Business Model Canvas Research

Arvinas’s Bayer AG alliance adds a second large pharma partner to its degradation platform, supporting discovery and development of targeted protein degraders. This kind of split-partner model helps spread scientific and financial risk across collaborators, instead of leaning on one company.

• Large-scale pharma validation
• Supports degrader R&D
• Diversifies partner risk

Arvinas, Inc. leans on a CRO and CMO network to run clinical studies and secure clinical-grade supply for oral candidates, reducing fixed overhead while keeping programs moving. In 2025, Arvinas reported R&D spending of about $517 million, underscoring how partner-heavy its pipeline is.

• CROs run trials and data capture
• CMOs supply clinical-grade drug
• Partners support oral candidates

Arvinas, Inc. uses regulatory and medical affairs to file INDs, trial amendments, and other submissions, while also working with regulators and investigators on study design. This keeps its degrader pipeline aligned with FDA expectations and is a direct gate to approval.

• Files INDs and protocol changes
• Aligns studies with regulators
• Supports approval path

Arvinas, Inc. uses alliance management to run multi-party pharma deals, set data-sharing rules, and define program scope, so its platform science can move into funded programs. In 2025, this model was still central to its partner-driven R&D, with collaboration revenue tied to milestone and reimbursement terms.

• Negotiate milestones and scope
• Manage pharma data sharing
• Turn science into funded programs

Arvinas, Inc., founded in 2013 and based in New Haven, Connecticut, treats its scientific and clinical team as a core key resource. Its scientists and development professionals cover chemistry, biology, and clinical operations, which supports the company’s protein-degradation pipeline and late-stage trial execution.

• Founded in 2013
• Headquartered in New Haven, Connecticut
• Core skills: chemistry, biology, clinical ops

Arvinas relies on partner data and funding as a key resource because alliances can bring non-dilutive cash and outside validation, while shared preclinical and clinical data can speed program picks. In its latest filings, partnership economics still matter more than product sales for funding development, so each deal can shape which programs move first.

• Non-dilutive partner cash funds R&D.
• Shared data speeds program selection.
• Deal terms drive resource allocation.

Protein degradation can help Arvinas, Inc. tackle treatment resistance by removing the target protein instead of only blocking its active site, which may be more durable in advanced cancers. This matters where conventional inhibitors often lose effect as tumors adapt, and it supports longer control in hard-to-treat disease.

• Removes the protein, not just blocks it
• May delay resistance in advanced cancers
• Fits tumors that evade inhibitors

Arvinas, Inc.'s partner-validated platform is backed by large pharma alliances, including Pfizer, which signals outside confidence in the science and its commercial fit. These deals help de-risk the platform for investors and buyers because they show repeatable validation, not just internal claims.

• Big pharma backing lifts credibility.
• External deals validate market demand.
• Partnerships reduce platform risk.

Arvinas, Inc. uses investor updates to shape confidence in its clinical-stage pipeline, especially around data readouts, cash runway, and partnering. In 2025, that mattered because the company had no commercial product revenue, so capital access depended on clear, timely disclosure and proof of execution.

• Data readouts move the share price
• Cash runway guides financing risk
• Partnering supports future funding

Arvinas, Inc. reaches patients mainly through Phase 1-3 clinical studies, so trust is built around investigator education, site support, and tight safety monitoring. Because the relationship runs through healthcare providers, enrollment quality matters more than scale: one delayed site activation can slow access for every patient at that center.

• Provider-led access
• Trial education drives enrollment
• Safety monitoring sustains trust

Peer-reviewed publications are a key scientific channel for Arvinas, Inc.: they publish mechanism, safety, and efficacy data that clinicians and researchers can verify in journals. In 2025, Arvinas reported $0 revenue and a $308.4 million net loss in FY2024, so published evidence remains central to credibility while the pipeline advances.

• Builds trust with doctors and researchers
• Shows mechanism, safety, and efficacy
• Supports pipeline validation at low cost

Arvinas, Inc. uses INDs, amendments, and future NDA filings as formal channels to move R and D into FDA review, and this step is what turns lab data into a path to revenue. Its 2025 SEC filings show the company remained in active clinical development, with regulatory work tied to every new study and label-expansion step.

These submissions matter because commercialization cannot start without them: each filing opens the door to trial dosing, then approval review, then market entry. In plain terms, no IND or NDA path means no product launch.

• INDs open the FDA trial path
• Amendments expand ongoing studies
• NDA filings support commercialization

Large pharmaceutical partners are Arvinas, Inc.'s core business customers. Pfizer, Genentech, Roche, and Bayer fund development, co-develop assets, and can commercialize approved products, so this segment is the main driver of partnership revenue.

• Pfizer, Genentech, Roche, Bayer
• Fund, co-develop, commercialize
• Main source of partnership revenue

If approved, Arvinas, Inc.’s access will hinge on reimbursement, prior authorization, and formulary placement, so hospitals, insurers, and integrated delivery networks become the key downstream buyers. In the U.S., those payers shape access for more than 300 million covered lives, so adoption is a contracting issue as much as a clinical one.

• Reimbursement drives uptake.
• Hospitals and insurers decide access.
• Integrated delivery networks influence scale.

Arvinas, Inc.'s general and administrative costs cover finance, legal, HR, and investor relations, so they support the public-company structure rather than lab work. In fiscal 2025/2026 terms, these are fixed overhead costs that stay necessary even when R&D spend drives the main business.

• Finance, legal, HR, IR
• Public-company overhead
• Non-laboratory expense

IP and partnering costs are a core drag on Arvinas, Inc. because patent filing, defense, and contract work sit inside the 2025 R&D and G&A base, while collaboration talks and alliance management need steady legal and BD time. These outlays protect the platform and help turn it into license and milestone income.

• Protect patents and freedom to operate
• Pay for contract and legal work
• Run alliance talks and partner oversight
• Support platform monetization

Arvinas' royalty stream is still option value: in FY2025, it had not recognized royalty revenue because partnered assets had not yet generated sales, so the line item was $0. Once a partnered drug reaches market, even a low-single-digit royalty can create high-margin, long-duration income with little commercial burden, making royalties a major value-capture lever.

• FY2025 royalty revenue: $0
• Upside starts at market launch
• High margin, low burden

Future product sales would matter only if Arvinas, Inc. launches an approved therapy itself; today, its model is still driven by collaboration revenue, not product sales. As of its latest public filings, Arvinas has 0 marketed products, so this stream is a long-term option that depends on regulatory approval, manufacturing, and a successful launch.

• 0 commercial products today
• Direct sales would start after approval
• Still a future, not core, revenue stream